Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2352-2358

  Gómez, Henry ^a   Mas, Luis ^a   Casanova, Luis ^a   Pen, Daniel Lee Kay ^a   Santillana, Sergio ^a   Valdivia, Segundo ^a   Otero, Jorge ^a   Rodriguez, Wuilbert ^a   Carracedo, Carlos ^a   Vallejos, Carlos ^a,b  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^b UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FEVER; GERIATRIC CARE; HUMAN; HYPOTENSION; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

EID: 0345131723     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2352     Document Type: Article

References (39)

1. d'Amore F, Brincker H, Christensen BE, et al: Non-Hodgkin's lymphoma in the elderly. Ann Oncol 3:379-386, 1992
2. Moller Jensen O, Esteve J, Moller H, et al: Cancer in European community and its member states. Eur J Cancer 12:1167-1256, 1990
3. Balducci L, Parker M, Sexton W, et al: Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 16:76-84, 1989
4. Kimmick GG, Fleming R, Muss HB, et al: Cancer chemotherapy in older patients. A tolerability perspective. Drugs Aging 10:34-49, 1997
5. Egorin MJ: Cancer pharmacology in the elderly. Semin Oncol 20:43-49, 1993
6. Repetto L, Vercelli M, Simoni A, et al: Comorbid conditions among elderly cancer patients. Ann Oncol 5:58, 1994 (abstr 0288)
7. Lipschitz D: Age-related declines in hematopoietic reserve capacity. Semin Oncol 22:3-5, 1995 (suppl 1)
8. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Eng J Med 328:1002-1006, 1993
9. Epelbaum R, Faraggi D, Ben-Arie Y, et al: Survival of diffuse large-cell lymphoma. Cancer 66:1124-1129, 1990
10. Bertini M, Freilone R, Vitolo U, et al: P-VEBEC: A new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 5:895-900, 1994
11. Gómez H, Santillana S, Casanova L, et al: Dose-intensity chemotherapy improves disease-free survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with conventional CHOP. Eur J Cancer 31A: 168, 1995 (suppl 5, abstr 802)
12. Velasquez W, McLaughlin P, Tucker S, et al: ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12:1169-1176, 1994
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete information. J Am Stat Assoc 53:457-481, 1985
14. Lichtman SM: Lymphoma in the older patient. Semin Oncol 22:S25-S28, 1995 (suppl 1)
15. Armitage J, Potter J: Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications of advancing age. J Am Geriatr Soc 32:269-273, 1982
16. Dixon DO, Neilan B, Jones SE, et al: Effect of age on therapeutic outcome in patients with diffuse-histiocytic lymphoma: The Southwest Oncology Group experience. J Clin Oncol 4:295-305, 1986
17. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Eng J Med 325:164-170, 1991
18. Pettengell R, Gurney H, Radford J, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
19. Vose JM: Cytokine use in the older patient. Semin Oncol 22:6-8, 1995 (suppl 1)
20. Guerci A, Lederlin P, Reyes F, et al: Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Ann Oncol 7:966-969, 1996
21. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993
22. Shipp M: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "High-Risk" disease? Blood 83:1165-1173, 1994
23. Kwak LW, Halpern J, Olshen RA, et al: Dose-intensity (DI): Relationship to prognostic factors for diffuse large cell lymphoma. J Clin Oncol 8:963-977, 1990
24. Meyer RM, Browman GP, Samosh ML, et al: Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13:2386-2393, 1995
25. Sonneveld P, de Ridder M, van der Lelie, et al: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13:2530-2539, 1995
26. Epelbaum R, Haim N, Leviov M, et al: Full-dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma. Acta Oncol 34:87-91, 1994
27. Ansell SM, Falkson G: A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma. Ann Oncol 4:172-175, 1993
28. Martelli M, Guglielmi C, Coluzzi S, et al: P-VABEC: A prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:2362-2369, 1993
29. Zagonel V, Fratino L, Sacco C, et al: Reducing chemotherapy-associated toxicity in elderly cancer patients. Cancer Treat Rev 22:223-244, 1996
30. Balducci L, Mowry K: Pharmacology and organ toxicity of chemotherapy in older patients. Oncology 6:62-68, 1992
31. Chi KH, Chen CH, Chan WK, et al: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 13:2620-2628, 1995
32. Bregni M, Siena S, Di Nicola M, et al: Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 14:628-635, 1996
33. Mayordomo JI, Rivera F, Díaz-Puente T, et al: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87:803-808, 1995
34. Bastion Y, Blay JY, Divine M, et al: Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival. A Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years. J Clin Oncol 15:2945-2953, 1997
35. Vose JM, Armitage JO, Weisenburger DD, et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 6:1838-1844, 1988
36. McMaster ML, Johnson DH, Greer JP, et al: A brief duration combination chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 9:741-747, 1991
37. O'Reilly SE, Klimo P, Connors JM: Low-dose ACOP-B and VABE: Weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol 9:741-747, 1991
38. Chatta GS, Price TH, Allen RC, et al: Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 84:2923-2929, 1994
39. Chatta GS, Dale DC: Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Drug Aging 9:37-47, 1996